iiinova — where your digital self keeps evolving

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 12/10/2026

A new MSK study by Dr. Zsofia Stadler & Dr. Luis Diaz Jr. found that limiting genetic testing to patients under 50 would have missed 72% of those with inherited cancer mutations. Knowing about these mutations can help guide treatment & help people understand cancer risk. bit.ly/4yLPpwY

010

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 07/10/2026

Congrats to MSK's most recent awards and appointments, including Dr. Zsofia Stadler for being appointed Chief of MSK’s Clinical Genetics Service, Dr. Seungjae Lee for being named a finalist for the 2026 Blavatnik Regional Awards for Young Scientists, and more: bit.ly/4zjtfSo

041

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 07/10/2026

🎉 Congratulations to MSK radiation oncologists Dr. Christopher Barker, Dr. Daphna Gelblum, and Dr. Abraham Wu on being named 2026 ASTRO Fellows, recognizing their contributions to radiation oncology! #ASTRO2026

010

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 02/10/2026

The FDA recently approved a targeted therapy called lirafugratinib (Lyrfigtu) for people with advanced cholangiocarcinoma that has a genetic change called an FGFR2 fusion. The clinical trial that resulted in the drug’s approval was led by MSK's Dr. Alison Schram. bit.ly/4ALO4Yc

141

Reposted by Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Continuing Medical Education @mskcme.bsky.social · 30/09/2026

Join us in NYC or virtually on Oct. 8–9 to explore advances and key questions across the continuum of #ProstateCancer care, featuring tumor boards, panel discussions, and debates with multidisciplinary experts from @mskcancercenter.bsky.social and other leading institutions. 🔗 bit.ly/Prostate2026CME

022

Reposted by Memorial Sloan Kettering Cancer Center

MSKEducation @mskeducation.bsky.social · 01/10/2026

To all #MSKPostdocs - THANK YOU for your significant contributions to the @mskcancercenter.bsky.social research community! MSK-PDA we are proud to celebrate you! #NPAW2026

National Postdoc Appreciation Week
September 2026

021

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 01/10/2026

MSK scientists from the Scott Lowe Lab and the Daniel Heller Lab engineered nanoparticles to target cells driving scarring around many liver and lung tumors. In mice, this reduced scarring and helped immunotherapy shrink tumors that resisted treatment.

143

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 30/09/2026

Join MSK experts Oct. 2, at ET for a complimentary virtual symposium on multidisciplinary care for pediatric brain and spinal tumors. Participants will hear practical updates on the latest advances in multidisciplinary neuro-oncology care. Learn more and register: bit.ly/4xTYrGQ

010

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 30/09/2026

The FDA has approved the drug belzutifan in combination with lenvatinib for patients with a type of #kidneycancer called clear cell renal cell carcinoma (ccRCC). The approval was based on a clinical trial led by Dr. Robert Motzer, a genitourinary medical oncologist at MSK. bit.ly/4hiaiJO

021

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 30/09/2026

Coming up at #ASTRO26: MSK radiation oncologist Dr. Brandon Imber will present research on bridging radiotherapy and systemic inflammation before CAR T-cell therapy for B-cell lymphomas. 🗓️ Wednesday, September 30 | 9:15 a.m. ET Learn more: bit.ly/3VCyz4K

021

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 29/09/2026

Tomorrow at #ASTRO26: MSK radiation oncologist Dr. Kevin Boehm will present research using pathology images and clinical tumor sequencing from more than 60,000 patients to model cancer subtypes and molecular features. 🗓️ Wednesday, September 30 | 8:20 a.m. ET Learn more: bit.ly/4ACpx7M

022

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 29/09/2026

At #ASTRO26, MSK researchers presented studies on organ preservation and circulating tumor DNA (ctDNA) monitoring in rectal and anal cancers. Their work examines how treatment and follow-up care could be tailored to each patient. Read about the studies and their findings: bit.ly/4hsBnsA

012

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 29/09/2026

Coming up at #ASTRO26: MSK radiation oncologist Dr. Marsha Reyngold will present two- and three-year overall survival findings after ablative MR-guided radiotherapy for localized pancreatic cancer without surgery. 🗓️ Tuesday, September 29 | 5:20 p.m. ET Learn more: bit.ly/3TnVS1F

071

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 29/09/2026

Coming up at #ASTRO26: MSK radiation oncologist Dr. Sean McBride will present “Intensify, Shorten, or Personalize? Modern Approaches to Post-prostatectomy RT.” 🗓️ Tuesday, September 29 | 12:30 p.m. ET

031

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 28/09/2026

New research from MSK shows how a metabolite boosts immune cells against cancer; adds to the understanding of how colorectal cancer spreads; and more: bit.ly/4z2sJbt

031

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 28/09/2026

Today at #ASTRO26: MSK radiation oncologist Dr. Alexander Goglia will present five-year outcomes from a trial of MR-guided SBRT with a focal DIL boost for intermediate-risk prostate cancer. 🗓️ Monday, September 28 | 3:10 p.m. ET Learn more: bit.ly/47lXHPT

022

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 28/09/2026

Coming up at #ASTRO26: MSK's Dr. George Naoum will present a validated tool that predicts the risk of invasive breast cancer recurrence for patients with N1mic disease treated with or without nodal radiotherapy. 🗓️ Monday, September 28 | 8:30 a.m. ET Learn more: bit.ly/4hsThvo

011

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 27/09/2026

Coming up at #ASTRO26: MSK radiation oncologist Dr. Nancy Lee will present a pooled analysis of trials studying FMISO PET-guided, lower-dose radiation for HPV-positive oropharyngeal cancer. 🗓️ Sunday, September 27 | 3 p.m. ET Learn more: bit.ly/4yYOmcE

121

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 23/09/2026

Coming up at #IMS26: MSK myeloma specialist & cellular therapist Dr. Sham Mailankody will discuss bispecifics in the outpatient setting during a Meet the Experts session. 🗓️ Thursday, September 24 | 12 p.m. BT / 7 a.m. ET

021

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 23/09/2026

Researchers in Dr. Agnel Sfeir’s lab at MSK identified a hidden structural weakness in rogue DNA found in aggressive cancers. In lab studies, blocking the protein that repairs this DNA caused it to become unstable and gradually disappear from cancer cells. Learn more: bit.ly/3V8pyjO

020

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 21/09/2026

🚨 The FDA has approved imlunestrant (Inluriyo™) in combination with abemaciclib (Verzenio®) for patients with ER-positive, HER2-negative advanced #breastcancer with an ESR1 gene mutation who were previously treated with hormone therapy.

121

Reposted by Memorial Sloan Kettering Cancer Center

MSKEducation @mskeducation.bsky.social · 16/09/2026

🎉 Congratulations to our 10 MSK Postdoc Slam finalists! 👏 You were all fantastic and it was truly inspiring to learn about the incredible and diverse work happening at @mskcancercenter.bsky.social. Our #MSKPostdocs gave the judges a real challenge… choosing winners was no easy task! 🤗

131

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 11/09/2026

MSK researchers are using AI to design better proteins for CAR T cell therapy. In mouse models, an AI-designed binder from Dr. Caleb Lareau's lab controlled tumor growth significantly better than binders used in FDA-approved CAR T therapy targeting BCMA. Learn more: bit.ly/4cGeaSc

041

Reposted by Memorial Sloan Kettering Cancer Center

MSK Department of Medicine @mskdeptofmed.bsky.social · 04/09/2026

Don't miss the Third Annual Kyle Barlogie Plasma Cell Disorders Symposium from October 9–12, 2026. Register by September 11 to get the early-bird reduced rate! Register here: cvent.me/7lkMy2 @mskcancercenter.bsky.social @mayocliniccancer.bsky.social

Text overlay on graphic announces the "3rd Annual Kyle Barlogie 2026 Plasma Cell Disorders Symposium" with details: "Register Today! October 9 - 10, 2026, In-person, New York, NY.

011

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 08/09/2026

🎉 Congrats to MSK's most recent awards and appointments, including Dr. Tuomas Tammela for receiving a 2026 Stephenson Global Scholar Grant by the Stephenson Global Pancreatic Cancer Research Institute (SGPCRI), and more: bit.ly/46L9mY9

000

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 03/09/2026

🚨 New research in @nejm.org: In a phase 1/2 trial led by MSK’s @kcarbourmd.bsky.social, more than 30% of patients with previously treated metastatic lung cancer responded to daraxonrasib. The targeted therapy could expand treatment options for people with lung cancer. More: bit.ly/4gACirQ

011

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 31/08/2026

What if a blood test could detect lymphoma more precisely than an imaging scan? MSK's Dr. Mark Roschewski is studying how blood-based tests for circulating tumor DNA may help guide treatment decisions and determine whether cancer remains after therapy. Learn more: bit.ly/4zZOwlx

0106

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 26/08/2026

The FDA has approved #daraxonrasib for certain patients with metastatic pancreatic cancer. MSK’s Dr. Eileen O'Reilly led the phase 3 trial showing it doubled median survival compared with chemotherapy. Learn more about the approval and what it could mean for patients: bit.ly/4zM7xYv

052

Reposted by Memorial Sloan Kettering Cancer Center

Stanford Department of Medicine @stanforddeptmed.bsky.social · 24/08/2026

New on #FutureOfMedicine with #StanDOM's @euanashley.bsky.social: @mskcancercenter.bsky.social Chief Scientific Officer Ross Levine discusses how a microscopic change in a single gene (JAK2) helped reshape how doctors understand & treat a group of #BloodCancers. bit.ly/4hGuq93

032

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 21/08/2026

New clinical trial data led by MSK’s Dr. Robert Motzer supports a novel combination therapy for patients with advanced clear cell renal cell carcinoma whose disease progressed after immunotherapy. The findings point to a potential new treatment option. Learn more: bit.ly/45HXSUT

021

Reposted by Memorial Sloan Kettering Cancer Center

IMPACTT Microbiome @impactt-microbiome.bsky.social · 18/08/2026

Meet Plenary Speaker Dr. Gretchen Diehl (@diehllab-mskcc.bsky.social), Member of the Immunology Program, and Catherine and Frederick R. Adler Chair for Junior Faculty @mskcancercenter.bsky.social, who will speak about Avoiding pyroptosis after E. coli inflammasome activation at #HavingIMPACTT2026

176

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 17/08/2026

New research from MSK uncovers why some leukemia patients stop responding to promising new drugs; examines how bone’s hardness shapes the immune battle against metastasis; shows how a telehealth tobacco treatment program helps cancer patients quit smoking; and more: bit.ly/3U61gGA

000

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 10/08/2026

The FDA has expanded approval of Pluvicto® (¹⁷⁷Lu-PSMA-617) as an initial treatment for people with metastatic prostate cancer whose tumors are positive for the PSMA protein. The approval is based on results from the phase 3 PSMAddition trial, led in the U.S. by MSK's Dr. Michael Morris.

mskcc.org

FDA Expands Approval of Pluvicto® for Metastatic Prostate Cancer: Targets a Protein Called PSMA | Memorial Sloan Kettering Cancer Center

Learn more about a new radiopharmaceutical treatment for prostate cancer approved by the FDA for more patients.

011

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 06/08/2026

Inherited #BRCA1 and #BRCA2 mutations may affect how breast tumors respond to treatment, according to a study of more than 5,800 patients. MSK's Dr. Pedram Razavi discussed the findings with @targetedonc.bsky.social and how they could inform future treatment strategies: bit.ly/4hMRBym

021

Reposted by Memorial Sloan Kettering Cancer Center

Benjamin D. Greenbaum @bengrbm.bsky.social · 04/08/2026

We are hiring fellows for a pilot initiative at @mskcancercenter.bsky.social – The Theory Group. The Group is centered around tumor-immune interactions and, post-AI, theoretical approaches that can unlock fundamental questions with translational impact. msk.wd108.myworkdayjobs.com/MSKCC_Career...

msk.wd108.myworkdayjobs.com

Research Scholar

About Us: The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate, expert ca...

083

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 03/08/2026

Congrats to MSK's most recent awards and appointments, including Dr. Joan Massagué for receiving the Kennedy Award from the Institut d’Estudis Nord-americans (IEN); Dr. Daniel Heller for being named a Gray Foundation Grant Recipient; and more: bit.ly/4wp853H

001

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 30/07/2026

The FDA has approved zidesamtinib for advanced ROS1-positive non-small cell #lungcancer that stopped responding to other #ROS1 drugs. MSK thoracic medical oncologist Dr. Alexander Drilon led the clinical trial. Learn more: bit.ly/4q7Bluh

021

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 30/07/2026

The FDA has approved zenocutuzumab for adults with advanced, inoperable, or metastatic cholangiocarcinoma driven by an NRG1 gene fusion. The approval is based on a trial led by MSK’s Dr. Alison Schram giving patients with limited treatment options a new choice. Learn more: bit.ly/4fGFXTf

041

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 17/07/2026

Calling all fourth-year medical students interested in #RadOnc! 🩺 Join the Chief Residents from MSK for a virtual info session about MSK's Radiation Oncology Residency Program. Learn more about our training program, research opportunities, and resident life. Register: bit.ly/4vKnN9e

011

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 16/07/2026

(1/2) Five years after her passing, the final study from the lab of the late MSK developmental biologist and department chair Dr. Kathryn Anderson has been published, revealing how a critical signaling molecule called WNT tells cells in the embryo what they will become.

130

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 14/07/2026

MSK's Dr. Lydia Finley and researchers study #cellmetabolism, aka how cells convert nutrients into the various molecules that they need to function. By shedding new light on fundamental biology, the researchers aim to find new strategies that could work against cancer. bit.ly/4vwCNHE

010

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 13/07/2026

(1/2) Scientists from MSK and @weillcornell.bsky.social found that a small subset of T cells, called stem T cells, are responsible for making new T cells and continuously replenishing them in chronic disease.

163

Reposted by Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Continuing Medical Education @mskcme.bsky.social · 09/07/2026

Join is for an inaugural two-day virtual symposium @mskcancercenter.bsky.social highlighting advances in surgical oncology, from perioperative care and minimally invasive approaches to complex emergencies, technology, workforce development, and health equity. Learn more: bit.ly/SurgOnc2026

011

Reposted by Memorial Sloan Kettering Cancer Center

Waggoner Lab @labwaggoner.bsky.social · 09/07/2026

Forum @cp-cellhostmicrobe.bsky.social Operationalizing microbiome ecology in cancer care www.cell.com/cell-host-mi... @mskcancercenter.bsky.social

122

Reposted by Memorial Sloan Kettering Cancer Center

STEMCELL Science News @stemcellsciencenews.com · 10/07/2026

Novel #immunotherapy approaches such as T cell-engager therapies, CD40 agonists, and HSV-TK gene therapy have shown early promise for the treatment of #ProstateCancer. Read the review from Drs. Dallos, Gaffney, and @mskcancercenter.bsky.social collaborators. 📖 🔗 go.nature.com/4vRA5x7

022

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 09/07/2026

The FDA has granted full approval for an engineered cell therapy called afamitresgene autoleuecel (Tecelra®, also known as afami-cel) for treating advanced synovial sarcoma. More about the clinical trials resulting in the drug’s approval, led by MSK's Dr. Sandra D’Angelo: bit.ly/4eVcTZ4

032

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 07/07/2026

New research from MSK investigates how a natural antifungal compound produced by helpful gut bacteria might help protect vulnerable patients; finds that a protein “fingerprint” in blood could predict dangerous clots in cancer patients; and more: bit.ly/4vzMuFj

154

Reposted by Memorial Sloan Kettering Cancer Center

Blood Journals Portfolio @bloodjournals.hematology.org · 01/07/2026

We're thrilled to welcome a new Associate Editor to Blood today! Dr. Omar Abdel-Wahab is the Evnin Family Chair of Molecular Pharmacology at @mskcancercenter.bsky.social where he also serves as Chair of the Molecular Pharmacology Program in the Sloan Kettering Institute. #NewEditor

042

Reposted by Memorial Sloan Kettering Cancer Center

Waggoner Lab @labwaggoner.bsky.social · 01/07/2026

LEF1 and niche-derived factors are identified as essential regulators of T cell stemness across chronic diseases @cellcellpress.bsky.social @mskcancercenter.bsky.social @dbetel.bsky.social et al www.cell.com/cell/fulltex...

074